ASH 2025: Highlights

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential thrombocythemia

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma

Rusfertide provides durable control of haematocrit and phlebotomy reduction in polycythemia vera

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL

COVID-19 IgG antibodies induce endothelial activation, barrier dysfunction, and a prothrombotic state

Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses in relapsed/refractory multiple myeloma

MRD validated as a surrogate endpoint for survival in AML

Zamtocabtagene autoleucel improves event-free survival vs standard of care in second-line r/r LBCL

Complement-bound procoagulant platelets predict thrombosis in antiphospholipid syndrome

Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis